Endocyte Inc (NASD: ECYT) lost over 60% of its market capitalization after announcement that its cancer drug candidate was shown not to increase survival in a subset of ovarian cancer patients during a phase 2 clinical trial. ECYT stock dropped below $4 following this news on December 14th and slowly declined all week long. Done […]